Johnson & Johnson (JNJ)
Quarterly indicator history, curated for fast reading.
Exchange
NYSE
IPO Date
Sep 25, 1944
Shares Outstanding
2.41B
Market Cap
$561.77B
Price
$233.10+5.85 (+2.57%)● Live
Rule of 402025 Q3
40.5
✓ Passing
Revenue Growth YoY+6.8%
+
FCF Margin+33.7%
History
Revenue
Unit: USD · Scale: ones
2025 Q4
$24,564,000,000
EPS
Unit: USD per share · Scale: ones
2025 Q4
$2.1
P/E Ratio
Unit: x · Scale: ones
2025 Q4
18.73
Free cash flow
Unit: USD · Scale: ones
2025 Q3
$8,088,000,000
Company timeline
Earnings release dates
| Quarter | End date | Publication date | Source |
|---|---|---|---|
| 2025 Q4 | 2025-12-31 | 2026-01-21 | Link |
| 2025 Q3 | 2025-09-30 | 2025-10-14 | Link |
| 2025 Q2 | 2025-06-30 | 2025-07-16 | Link |
| 2025 Q1 | 2025-03-31 | 2025-04-15 | Link |
| 2024 Q4 | 2024-12-31 | 2025-01-22 | Link |
| 2024 Q3 | 2024-09-30 | 2024-10-15 | Link |
| 2024 Q2 | 2024-06-30 | 2024-07-17 | Link |
| 2024 Q1 | 2024-03-31 | 2024-04-16 | Link |
| 2023 Q4 | 2023-12-31 | 2024-01-23 | Link |
| 2023 Q3 | 2023-09-30 | 2023-10-17 | Link |
| 2023 Q2 | 2023-06-30 | 2023-07-20 | Link |
| 2023 Q1 | 2023-03-31 | 2023-04-18 | Link |
| 2022 Q4 | 2022-12-31 | 2023-01-24 | Link |
| 2022 Q3 | 2022-09-30 | 2022-10-18 | Link |
| 2022 Q2 | 2022-06-30 | 2022-07-19 | Link |
| 2022 Q1 | 2022-03-31 | 2022-04-19 | Link |
| 2021 Q4 | 2021-12-31 | 2022-01-25 | Link |
| 2021 Q3 | 2021-09-30 | 2021-10-19 | Link |
| 2021 Q2 | 2021-06-30 | 2021-07-21 | Link |
| 2021 Q1 | 2021-03-31 | 2021-04-20 | Link |
| 2020 Q4 | 2020-12-31 | 2021-01-26 | Link |
| 2020 Q3 | 2020-09-30 | 2020-10-13 | Link |
| 2020 Q2 | 2020-06-30 | 2020-07-16 | Link |
| 2020 Q1 | 2020-03-31 | 2020-04-14 | Link |
Leadership
Key Players
Joaquin Duato
Chairman & Chief Executive Officer
CEO since January 2022, Chairman since January 2023. Leads ~138,000 employees globally, directing an R&D portfolio of nearly $17B annually across pharmaceuticals and MedTech.
Joseph J. Wolk
Executive Vice President, Chief Financial Officer
Oversees global finance, capital markets and investor relations. Maintains AAA-equivalent balance sheet with net debt-to-EBITDA under 1.5x.
Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Leads commercial strategy for ten blockbuster therapies generating ~$57B in sales across oncology, immunology, neuroscience, and cardiology.
Tim Schmid
Executive Vice President, Worldwide Chairman, MedTech
Runs $30B+ medical-technology portfolio spanning 300+ platforms and 8,000 patents, including surgical robotics and AI-guided endoscopy.
John C. Reed
Executive Vice President, Innovative Medicine, R&D
M.D., Ph.D. Directs end-to-end drug discovery pipeline with 105 clinical assets including 40 in Phase 3. Integrates AI-enabled research and 400 academic/biotech partners.
Vanessa Broadhurst
Executive Vice President, Global Corporate Affairs
Leads corporate marketing, communications, health-equity initiatives and philanthropy across 100+ markets.
Liz Forminard
Executive Vice President, Chief Legal Officer
Heads worldwide legal, compliance, privacy and ESG. Manages complex litigation including 63,000+ talc-related claims.
Kristen Mulholland
Executive Vice President, Chief Human Resources Officer
Crafts global talent strategy for 134,500+ employees. Women constitute 45% of global workforce and 50% of Executive Committee seats.
James Swanson
Executive Vice President, Chief Information Officer
Orchestrates digital strategy, cybersecurity and cloud platforms. Oversees $3B tech budget securing 15 petabytes of clinical and supply-chain data.
Kathryn E. Wengel
Executive Vice President, Chief Technical Operations & Risk Officer
Governs global supply chain delivering 80 billion doses/devices annually with 98% on-time service across 150 countries.
Mary C. Beckerle
Director
Chair of Science & Technology Committee. Distinguished Professor of Biology and Oncological Sciences.
Jennifer A. Doudna
Director
Nobel Prize-winning biochemist and co-inventor of CRISPR-Cas9 gene editing. Member of Science & Technology and Nominating & Corporate Governance Committees.
Marillyn A. Hewson
Director
Chair of Nominating & Corporate Governance Committee. Former Chairman, President and CEO of Lockheed Martin.
Paula A. Johnson
Director
Member of Nominating & Corporate Governance and Science & Technology Committees. President of Wellesley College.
Hubert Joly
Director
Chair of Audit Committee. Former Chairman and CEO of Best Buy. Member of Nominating & Corporate Governance Committee.
Mark B. McClellan
Director
Member of Regulatory Compliance & Sustainability and Science & Technology Committees. Former FDA Commissioner.
John G. Morikis
Director
Member of Audit and Compensation & Benefits Committees. Former Chairman, President and CEO of Sherwin-Williams.
Daniel E. Pinto
Director
Member of Audit and Compensation & Benefits Committees. President and COO of JPMorgan Chase.
Mark A. Weinberger
Director
Chair of Regulatory Compliance & Sustainability Committee. Member of Audit Committee. Former Global Chairman and CEO of EY.
Eugene A. Woods
Director
Chair of Compensation & Benefits Committee. President and CEO of Advocate Health, one of the largest nonprofit health systems in the US.
Nadja Y. West
Director
Member of Regulatory Compliance & Sustainability and Science & Technology Committees. Retired Lieutenant General and former US Army Surgeon General.
Short Interest
Short interest data unavailable for JNJ.